Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires confirmation. Methods: Type 2 diabetes patients newly diagnosed during 1999‐2005 and with 2 or more prescriptions of antidiabetic drugs were enrolled from the Taiwan’s National Health Insurance database. A total of 173 917 ever‐users and 21 900 never‐users of metformin were identified (unmatched cohort). A 1:1 matched‐pair cohort of 21 900 ever‐users and 21 900 never‐users based on a propensity score (PS) was created. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the PS. In addition, interactions with aspirin and statin were evaluated. Results: In the unmatched cohort, 619 never‐users and 2642 ever‐users developed HCC, with a respective incidence of 668.0 and 330.7 per 100 000 person‐years and an overall hazard ratio of 0.49 (95% confidence interval: 0.45‐0.54). The hazard ratios for the first (<25.7 months), second (25.7‐56.9 months) and third (>56.9 months) tertile of cumulative duration of metformin therapy were 0.89 (0.81‐0.98), 0.50 (0.46‐0.56) and 0.23 (0.21‐0.26) respectively. Analyses of the matched cohort showed an overall hazard ratio of 0.76 (0.67‐0.85), and the hazard ratios for the respective tertiles were 1.39 (1.19‐1.62), 0.77 (0.65‐0.91) and 0.37 (0.30‐0.45). Aspirin and statin were observed to have a significant interaction with metformin. Conclusions: Metformin was associated with a reduced risk of HCC in a dose‐response pattern. Users of both metformin and aspirin or metformin and statin had the lowest risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017) · Medicine · doi:10.1097/md.0000000000006888 · Cited by 89
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
Cited by
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Singal, A. G., Lampertico, P., & Nahon, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.025 · Cited by 1,102
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Glossmann, H. H., & Lutz, O. M. D. (2019) · Gerontology · doi:10.1159/000502257 · Cited by 149
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
“, which enrolled 21,900 ever- users and a matched- pair cohort of 21,900 never- users of metformin.[45] The results confirmed the chemo- preventive role of metformin, and the subanalysis assessing concomitant treatment with statins showed a potential protective synergistic effect.”
Result
Metadata
- Authors
- Tseng, C.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2018-06-29
- Volume
- 38
- Issue
- 11
- Pages
- 2018-2027
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2809909380
- Cited by
- 132
- References
- 3
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/liv.13872
- The paper
- Tseng, C. (2018). Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver International. https://doi.org/10.1111/liv.13872
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.